VITA 34 (V3V) AI Stock Analysis

• Market Cap: €106.33M
• Dividend Yield: N/A
• Average Volume (3M): 1.65K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.25
• Revenue Growth: 9.48%
• EPS Growth: -481.90%
• Country: DE
• Employees: 783
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.07
• Shares Outstanding: 17,640,104
• 10 Day Avg. Volume: 2,079
• 30 Day Avg. Volume: 1,645
• PEG Ratio: -0.01
• Price to Book (P/B): 5.08
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 13.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: €7.00 ▲(14.75% Upside)

The overall stock score is primarily influenced by the company's strong technical momentum, despite financial instability and poor valuation metrics. The stock's bullish trend is a significant positive, but the lack of profitability and cash flow issues weigh heavily on the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for VITA 34's services, suggesting a solid market position and potential for future expansion.

Industry Trends

The increasing interest in regenerative medicine and stem cell research provides a favorable backdrop for VITA 34, supporting long-term growth prospects.

Business Model

A diversified revenue model based on essential healthcare services ensures steady cash flow and resilience against market fluctuations.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder VITA 34's ability to reinvest in growth and sustain operations, impacting long-term viability.

High Leverage

Significant leverage increases financial risk, potentially limiting strategic flexibility and increasing vulnerability to economic downturns.

Cash Flow Issues

Negative cash flow growth limits the company's ability to fund operations and invest in future opportunities, posing a risk to long-term sustainability.

VITA 34 Business Overview & Revenue Model

Company Description

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

How the Company Makes Money

VITA 34 generates revenue primarily through the collection and storage services of umbilical cord blood stem cells. The company charges families a fee for the initial collection and processing of the stem cells, as well as an annual storage fee for maintaining the samples in their facility. Additionally, VITA 34 may generate revenue from partnerships with healthcare providers and hospitals, where they provide educational resources and services related to stem cell banking. Their business model is further supported by the growing demand for regenerative medicine and advancements in stem cell research, allowing them to capitalize on emerging therapies and treatments.

VITA 34 Financial Statement Overview

Summary

VITA 34 is facing financial difficulties, characterized by ongoing losses, high leverage, and weak cash flow generation. While there is some revenue growth, the company's profitability and financial stability are under pressure. The high debt levels and negative profitability metrics pose significant risks, requiring strategic measures to improve financial health.

Income Statement

VITA 34's income statement reflects a challenging financial position. The company has experienced modest revenue growth, with a TTM (Trailing-Twelve-Months) revenue growth rate of 2.35%. However, profitability metrics are concerning, with negative net profit and EBIT margins indicating ongoing losses. The gross profit margin has improved slightly to 27.61% in the TTM, but the company remains unprofitable, which is a significant weakness.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio of 1.50, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively low, suggesting limited financial stability. These factors highlight the company's financial vulnerability.

Cash Flow

Cash flow analysis reveals a significant decline in free cash flow, with a growth rate of -79.51% in the TTM. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is also weak, suggesting limited cash generation relative to losses. These metrics highlight cash flow constraints and liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	88.29M	82.18M	77.06M	68.94M	28.42M	20.07M
Gross Profit	25.41M	20.65M	28.24M	2.73M	12.44M	11.66M
EBITDA	2.89M	-443.00K	5.81M	-18.34M	949.00K	5.01M
Net Income	-9.86M	-12.14M	-1.86M	-27.39M	-3.93M	1.45M
Balance Sheet
Total Assets	159.53M	152.74M	158.36M	151.51M	177.95M	58.46M
Cash, Cash Equivalents and Short-Term Investments	13.05M	18.46M	17.42M	18.23M	35.26M	10.52M
Total Debt	19.35M	18.10M	21.57M	28.18M	32.32M	5.30M
Total Liabilities	147.28M	139.83M	135.58M	135.66M	136.00M	28.93M
Stockholders Equity	13.77M	14.13M	23.56M	16.50M	43.07M	29.55M
Cash Flow
Free Cash Flow	-386.00K	5.46M	5.06M	-10.92M	467.00K	3.33M
Operating Cash Flow	4.29M	8.65M	9.15M	-4.49M	2.73M	3.98M
Investing Cash Flow	-8.47M	-3.08M	-3.57M	-5.81M	24.87M	-252.00K
Financing Cash Flow	-1.55M	-6.09M	-5.09M	-6.27M	-4.70M	-2.43M

VITA 34 Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Positive. The current price of 6.1 is above the 20-day moving average (MA) of 5.74, above the 50-day MA of 5.58, and above the 200-day MA of 5.05, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 57.55 is Neutral, neither overbought nor oversold. The STOCH value of 31.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:V3V.

VITA 34 Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LIK	73 Outperform	€103.20M	21.94	23.66%	―	0.21%	7.53%
93M1	70 Outperform	€96.76M	-0.84	-43.43%	5.31%	180.19%	-196.45%
V3V	55 Neutral	€106.33M	-10.79	-50.39%	―	9.48%	-481.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MAK	41 Neutral	€20.45M	-1.52	―	―	6.87%	-94.85%